Triad Investment Management Buys Shares of 1,503 Amgen Inc. $AMGN

Triad Investment Management bought a new stake in Amgen Inc. (NASDAQ:AMGN) in the first quarter, Holdings Channel.com reports. The institutional investor bought 1,503 shares of the medical research company’s stock, valued at approximately $542,000.

A number of other institutional investors and hedge funds have also modified their holdings of AMGN. Brighton Jones LLC lifted its stake in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC grew its stake in Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares in the last quarter. Schnieders Capital Management LLC. grew its stake in Amgen by 29.3% during the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after acquiring an additional 5,853 shares in the last quarter. Main Street Financial Solutions LLC increased its holdings in shares of Amgen by 11.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock valued at $1,141,000 after purchasing an additional 416 shares during the period. Finally, Ieq Capital LLC increased its holdings in shares of Amgen by 5.1% in the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock valued at $15,120,000 after purchasing an additional 2,611 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.6%

AMGN opened at $366.24 on Wednesday. The company has a market capitalization of $197.66 billion, a PE ratio of 25.49, a price-to-earnings-growth ratio of 3.68 and a beta of 0.41. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $391.29. The business has a 50-day moving average of $348.98 and a 200-day moving average of $351.05.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter in the previous year, the business posted $4.90 EPS. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts forecast that Amgen Inc. will post 22.31 EPS for the current fiscal year.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.85% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on AMGN shares. Canaccord Genuity Group assumed coverage on shares of Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 price target for the company. Daiwa Securities Group dropped their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 13th. Weiss Ratings downgraded shares of Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 15th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Finally, Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus price target of $356.62.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.